Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approach

PurposeTo develop new selection criteria for active surveillance (AS) in intermediate-risk (IR) prostate cancer (PCa) patients.MethodsRetrospective study including patients from 14 referral centers who underwent pre-biopsy mpMRI, image-guided biopsies and radical prostatectomy. The cohort included biopsy-naive IR PCa patients who met the following inclusion criteria: Gleason Grade Group (GGG) 1-2, PSA < 20 ng/mL, and cT1-cT2 tumors. We relied on a recursive machine learning partitioning algorithm developed to predict adverse pathological features (i.e., >= pT3a and/or pN + and/or GGG >= 3).ResultsA total of 594 patients with IR PCa were included, of whom 220 (37%) had adverse features. PI-RADS score (weight:0.726), PSA density (weight:0.158), and clinical T stage (weight:0.116) were selected as the most informative risk factors to classify patients according to their risk of adverse features, leading to the creation of five risk clusters. The adverse feature rates for cluster #1 (PI-RADS <= 3 and PSA density < 0.15), cluster #2 (PI-RADS 4 and PSA density < 0.15), cluster #3 (PI-RADS 1-4 and PSA density >= 0.15), cluster #4 (normal DRE and PI-RADS 5), and cluster #5 (abnormal DRE and PI-RADS 5) were 11.8, 27.9, 37.3, 42.7, and 65.1%, respectively. Compared with the current inclusion criteria, extending the AS criteria to clusters #1 + #2 or #1 + #2 + #3 would increase the number of eligible patients (+ 60 and + 253%, respectively) without increasing the risk of adverse pathological features.ConclusionsThe newly developed model has the potential to expand the number of patients eligible for AS without compromising oncologic outcomes. Prospective validation is warranted.

Automated summary

The purpose of this study is to develop new selection criteria for active surveillance in intermediate-risk prostate cancer patients. A retrospective study was conducted on patients from 14 referral centers who underwent pre-biopsy mpMRI, image-guided biopsies, and radical prostatectomy. The results showed that PI-RADS score, PSA density, and clinical T stage were the most informative risk factors for classifying patients according to their risk of adverse features. Expanding the active surveillance criteria to include certain risk clusters can increase the number of eligible patients without increasing the risk of adverse pathological features.